Omer Faruk Kirlangic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Omer Faruk Kirlangic has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Serap Gur
Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Turkey
4 shared publications - Ecem Kaya-Sezginer
Department of Biochemistry Faculty of Pharmacy, Ankara University Ankara Türkiye
3 shared publications - Taner Ozgurtas
Department of Biochemistry, Gulhane Military Medical Academy, Ankara, Turkey
2 shared publications Armagan Khanam
Ankara University , Ankara , Turkey
1 shared publicationAshok Chatterjee
1 shared publicationAybuke Suveyda Tezgelen
Ankara University , Ankara , Turkey
1 shared publication
Latest Publications
- 28 October 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78 (6)
Metabolomic assessment of nitrogen mustard and 2-chloroethyl ethyl sulfide effects on human dermal fibroblast cell line
- 28 October 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78 (6)
Metabolomic assessment of nitrogen mustard and 2-chloroethyl ethyl sulfide effects on human dermal fibroblast cell line
- Open Access
- 30 January 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (2) , 266-273
Vascular endothelial growth factor (VEGF)-C and its receptors, soluble VEGFR-2 and VEGFR-3, in polycystic ovary syndrome
Objectives: Angiogenesis is involved in polycystic ovary syndrome (PCOS) progression. Vascular endothelial growth factor-C (VEGF-C) and its receptors are key angiogenic markers. The main objective of this study was to investigate the serum levels of VEGF-C and its receptors, soluble VEGF receptor 2 (sVEGFR-2) and VEGFR-3, in patients with PCOS and healthy controls and determine the link between serum levels of these VEGF-related proteins and the biochemical and hormonal data of patients with PCOS. Methods: Thirty-six women with PCOS and 30 controls were included in this study. The measurement of VEGF-C, sVEGFR-2, and VEGFR-3 levels in serum and routine biochemical and hormone analysis were performed. Results: In the PCOS group, significantly higher serum sVEGFR-2 levels and no significant differences in serum VEGF-C and VEGFR-3 were observed compared to the controls. Serum sVEGFR-2 levels exhibited positive associations with VEGF-C, VEGFR-3, total cholesterol, and anti-müllerian hormone (AMH) in women with PCOS. Moreover, a positive correlation between serum VEGF-C and VEGFR-3 concentrations was detected in patients with PCOS. The cutoff value of serum sVEGFR-2 was 4.24 ng/mL (sensitivity 68 %, specificity 64 %) to distinguish PCOS. Conclusions: Despite unaltered levels of serum VEGF-C and VEGFR-3, there was an association between circulating levels of sVEGFR-2 and these VEGF-related proteins. sVEGFR-2 could be a promising diagnostic biomarker for PCOS. Regarding the significant correlation between sVEGFR-2 and AMH, sVEGFR-2 could have an impact on the hormonal elements of PCOS. Further studies are warranted to fully understand the function of VEGF-C and its receptors in PCOS.
- 30 January 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (2) , 266-273
Open AccessVascular endothelial growth factor (VEGF)-C and its receptors, soluble VEGFR-2 and VEGFR-3, in polycystic ovary syndrome
Objectives: Angiogenesis is involved in polycystic ovary syndrome (PCOS) progression. Vascular endothelial growth factor-C (VEGF-C) and its receptors are key angiogenic markers. The main objective of this study was to investigate the serum levels of VEGF-C and its receptors, soluble VEGF receptor 2 (sVEGFR-2) and VEGFR-3, in patients with PCOS and healthy controls and determine the link between serum levels of these VEGF-related proteins and the biochemical and hormonal data of patients with PCOS. Methods: Thirty-six women with PCOS and 30 controls were included in this study. The measurement of VEGF-C, sVEGFR-2, and VEGFR-3 levels in serum and routine biochemical and hormone analysis were performed. Results: In the PCOS group, significantly higher serum sVEGFR-2 levels and no significant differences in serum VEGF-C and VEGFR-3 were observed compared to the controls. Serum sVEGFR-2 levels exhibited positive associations with VEGF-C, VEGFR-3, total cholesterol, and anti-müllerian hormone (AMH) in women with PCOS. Moreover, a positive correlation between serum VEGF-C and VEGFR-3 concentrations was detected in patients with PCOS. The cutoff value of serum sVEGFR-2 was 4.24 ng/mL (sensitivity 68 %, specificity 64 %) to distinguish PCOS. Conclusions: Despite unaltered levels of serum VEGF-C and VEGFR-3, there was an association between circulating levels of sVEGFR-2 and these VEGF-related proteins. sVEGFR-2 could be a promising diagnostic biomarker for PCOS. Regarding the significant correlation between sVEGFR-2 and AMH, sVEGFR-2 could have an impact on the hormonal elements of PCOS. Further studies are warranted to fully understand the function of VEGF-C and its receptors in PCOS.
- 1 January 2024
- Published by SAGE Publications in Stem Cells and Development
- Vol. 33 (1-2) , 43-53
Dual Strategy with Adipose-Derived Stem Cells and l -arginine Recovered Cavernosal Functions in a Rat Model of Radical Prostatectomy
As standard therapy for prostate cancer, radical prostatectomy (RP) causes cavernous nerve injury and increases fibrosis and hypoxia-induced penile structural alterations. This study aimed to determine the potential beneficial effects of adipose-derived stem cells (ADSCs) and L-arginine alone or in combination on the penile erection of a rat model of erectile dysfunction (ED) caused by bilateral cavernous nerve (CN) transection. Male rats (n=35) were randomized into five groups: Sham-operated; CN transection (4-wk); CN transection plus ADSCs (1x106 cells by intracavernosal injection); CN transection plus L-arginine (4wk, 10 mg/kg/day, oral); and ADSCs combined with L-arginine in CN transection. In vivo erectile responses and in vitro relaxant responses were measured. Western blot and immunohistochemistry analyses were used to determine the expression and localization of endothelial nitric oxide synthases (eNOS), neuronal NOS (nNOS), transforming growth factor-beta 1 (TGF-1), hypoxia-inducible factor-1 (HIF-1), and apoptosis markers (Bax and Bcl-2). The ratio of smooth muscle to collagen and nerve regeneration was calculated using Masson's trichrome and nicotinamide adenine dinucleotide phosphate (NADPH)-diaphorase staining. The combined treatment restored diminished erectile responses, endothelium-dependent acetylcholine, and electrical field stimulation-induced relaxation of the corpus cavernosum in rats with CN transection, whereas either monotherapy produced only partial improvements. All treatment regimens restored increases in the protein expression of HIF-1 and Bax in rodents with CN transection. The decrease in smooth muscle mass and NADPH-diaphorase-positive nerve fibers was partially ameliorated by monotherapy, whereas combined therapy led to recovery. These findings indicate that combined treatment with ADSCs and L-arginine may restore erectile function in rodents with CN transection by inhibiting hypoxia-induced neurotoxicity and preserving endothelium function and smooth muscle content.
- 1 January 2024
- Published by SAGE Publications in Stem Cells and Development
- Vol. 33 (1-2) , 43-53
Dual Strategy with Adipose-Derived Stem Cells and l -arginine Recovered Cavernosal Functions in a Rat Model of Radical Prostatectomy
As standard therapy for prostate cancer, radical prostatectomy (RP) causes cavernous nerve injury and increases fibrosis and hypoxia-induced penile structural alterations. This study aimed to determine the potential beneficial effects of adipose-derived stem cells (ADSCs) and L-arginine alone or in combination on the penile erection of a rat model of erectile dysfunction (ED) caused by bilateral cavernous nerve (CN) transection. Male rats (n=35) were randomized into five groups: Sham-operated; CN transection (4-wk); CN transection plus ADSCs (1x106 cells by intracavernosal injection); CN transection plus L-arginine (4wk, 10 mg/kg/day, oral); and ADSCs combined with L-arginine in CN transection. In vivo erectile responses and in vitro relaxant responses were measured. Western blot and immunohistochemistry analyses were used to determine the expression and localization of endothelial nitric oxide synthases (eNOS), neuronal NOS (nNOS), transforming growth factor-beta 1 (TGF-1), hypoxia-inducible factor-1 (HIF-1), and apoptosis markers (Bax and Bcl-2). The ratio of smooth muscle to collagen and nerve regeneration was calculated using Masson's trichrome and nicotinamide adenine dinucleotide phosphate (NADPH)-diaphorase staining. The combined treatment restored diminished erectile responses, endothelium-dependent acetylcholine, and electrical field stimulation-induced relaxation of the corpus cavernosum in rats with CN transection, whereas either monotherapy produced only partial improvements. All treatment regimens restored increases in the protein expression of HIF-1 and Bax in rodents with CN transection. The decrease in smooth muscle mass and NADPH-diaphorase-positive nerve fibers was partially ameliorated by monotherapy, whereas combined therapy led to recovery. These findings indicate that combined treatment with ADSCs and L-arginine may restore erectile function in rodents with CN transection by inhibiting hypoxia-induced neurotoxicity and preserving endothelium function and smooth muscle content.
- 31 August 2022
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 19 (4) , 371-376
Cytotoxic and Apoptotic Effects of the Combination of Borax (Sodium Tetraborate) and 5-Fluorouracil on DLD-1 Human Colorectal Adenocarcinoma Cell Line
Colorectal cancer (CRC) remains a crucial health problem due to the toxicity of 5-Fluorouracil (5-FU) as first-line chemotherapy agent for treating CRC. The anticancer effects of boron and its compounds have been shown in various cell lines. This study aimed to examine the cytotoxic and apoptotic effects of borax (sodium tetraborate) alone or along with 5-FU on human CRC cells, DLD-1. Cytotoxicity and apoptosis were determined by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, 4’,6-diamidino-2-phenylindole and annexin V/propidium iodide staining. The results showed that combined treatment revealed a significant time- and concentration-dependent cytotoxic effect on DLD-1 cells compared with borax or 5-FU treatment alone. The combination of borax and 5-FU induced a clear increase in the early apoptotic cell percentage, compared to the cells treated with monotherapies. Additionally, a significant increase in condensed and fragmented nuclei was detected in DLD-1 cells treated with the combination treatment compared with borax or 5-FU alone. Our current findings suggest that the combination of borax with 5-FU has a strong cytotoxic and apoptotic effect on the human CRC DLD-1 cells.
- 31 August 2022
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 19 (4) , 371-376
Cytotoxic and Apoptotic Effects of the Combination of Borax (Sodium Tetraborate) and 5-Fluorouracil on DLD-1 Human Colorectal Adenocarcinoma Cell Line
Colorectal cancer (CRC) remains a crucial health problem due to the toxicity of 5-Fluorouracil (5-FU) as first-line chemotherapy agent for treating CRC. The anticancer effects of boron and its compounds have been shown in various cell lines. This study aimed to examine the cytotoxic and apoptotic effects of borax (sodium tetraborate) alone or along with 5-FU on human CRC cells, DLD-1. Cytotoxicity and apoptosis were determined by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, 4’,6-diamidino-2-phenylindole and annexin V/propidium iodide staining. The results showed that combined treatment revealed a significant time- and concentration-dependent cytotoxic effect on DLD-1 cells compared with borax or 5-FU treatment alone. The combination of borax and 5-FU induced a clear increase in the early apoptotic cell percentage, compared to the cells treated with monotherapies. Additionally, a significant increase in condensed and fragmented nuclei was detected in DLD-1 cells treated with the combination treatment compared with borax or 5-FU alone. Our current findings suggest that the combination of borax with 5-FU has a strong cytotoxic and apoptotic effect on the human CRC DLD-1 cells.
- 25 February 2022
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 19 (1) , 48-53
Analysis of Changes in Serum Levels and Gene Expression Profiles of Novel Adipocytokines (Omentin, Vaspin, Irisin and Visfatin) and Their Correlation with Serum C-reactive Protein Levels in Women Diagnosed with Endometriosis
This study aimed to investigate the role of new adipocytokines (omentin, vaspin, irisin and visfatin) in the development of endometriosis and the relationship of these adipocytokines with the inflammatory marker, C-reactive protein (CRP) levels in serum. In this study, endometriosis (n=16) and control groups (n=14) were determined via ultrasound. Serum omentin, vaspin and irisin levels were measured by ELISA method. CRP levels in serum and the gene expression of visfatin and vaspin in whole blood samples were determined by clinical analyzer and the real-time polymerase chain reaction, respectively. Serum irisin and CRP levels in the endometriosis group were significantly higher than in the control group. Irisin protein levels demonstrated a positive correlation with body mass index and CRP in women diagnosed with endometriosis. No statistically significant difference was found in serum omentin and vaspin levels between groups. The visfatin and vaspin gene expression in whole blood samples from the endometriosis group was found to be significantly lower than the control group. Increased levels of serum irisin and decreased visfatin and vaspin gene expressions in blood may be considered as a potential biomarker in endometriosis. The identification of new adipocytokines, which demonstrate an alteration in the presence of endometriosis and the relationship between these adipocytokines and inflammation will facilitate the detection of mechanisms involved in endometriosis and will lead to the development of targeted therapy.
- 25 February 2022
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 19 (1) , 48-53
Analysis of Changes in Serum Levels and Gene Expression Profiles of Novel Adipocytokines (Omentin, Vaspin, Irisin and Visfatin) and Their Correlation with Serum C-reactive Protein Levels in Women Diagnosed with Endometriosis
This study aimed to investigate the role of new adipocytokines (omentin, vaspin, irisin and visfatin) in the development of endometriosis and the relationship of these adipocytokines with the inflammatory marker, C-reactive protein (CRP) levels in serum. In this study, endometriosis (n=16) and control groups (n=14) were determined via ultrasound. Serum omentin, vaspin and irisin levels were measured by ELISA method. CRP levels in serum and the gene expression of visfatin and vaspin in whole blood samples were determined by clinical analyzer and the real-time polymerase chain reaction, respectively. Serum irisin and CRP levels in the endometriosis group were significantly higher than in the control group. Irisin protein levels demonstrated a positive correlation with body mass index and CRP in women diagnosed with endometriosis. No statistically significant difference was found in serum omentin and vaspin levels between groups. The visfatin and vaspin gene expression in whole blood samples from the endometriosis group was found to be significantly lower than the control group. Increased levels of serum irisin and decreased visfatin and vaspin gene expressions in blood may be considered as a potential biomarker in endometriosis. The identification of new adipocytokines, which demonstrate an alteration in the presence of endometriosis and the relationship between these adipocytokines and inflammation will facilitate the detection of mechanisms involved in endometriosis and will lead to the development of targeted therapy.
- Open Access
- 20 March 2020
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 8 (2) , 132-155
The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
Cardiometabolic syndrome (CMS), as a bunch of metabolic disorders mainly characterized by type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, central adiposity, and abdominal obesity triggering androgen deficiency, is one of the most critical threats to men. Although many significant preclinical and clinical findings explain CMS, new approaches toward common pathophysiological mechanisms and reasonable therapeutic targets are lacking. To gain a further understanding of the role of androgen levels in various facets of CMS such as the constellation of cardiometabolic risk factors including central adiposity, dyslipidemia, insulin resistance, diabetes, and arterial hypertension and to define future directions for development of effective therapeutic modalities. Clinical and experimental data were searched through scientific literature databases (PubMed) from 2009 to October 2019. Evidence from basic and clinical research was gathered with regard to the causal impact and therapeutic roles of androgens on CMS. There are important mechanisms implicated in androgen levels and the risk of CMS. Low testosterone levels have many signs and symptoms on cardiometabolic and glycometabolic risks as well as abdominal obesity in men. The implications of the findings can shed light on future improvements in androgen levels and add potentially predictive risk for CMS, as well as T2DM, abdominal obesity to guide clinical management in the early stage. This comprehensive review refers to the association between androgens and cardiovascular health. A limitation of this study is the lack of large, prospective population-based studies that analyze the effects of testosterone treatment on CMS or mortality. Low testosterone levels have several common features with metabolic syndrome. Thus, testosterone may have preventive role in the progress of metabolic syndrome and subsequent T2DM, abdominal obesity, and cardiovascular disease and likely affect aging men's health mainly through endocrine and vascular mechanisms. Further studies are necessary to evaluate the therapeutic interventions directed at preventing CMS in men. Kirlangic OF, Yilmaz-Oral D, Kaya-Sezginer E, et al. The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts. Sex Med 2020;XX:XXX–XXX.
- 20 March 2020
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 8 (2) , 132-155
Open AccessThe Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
Cardiometabolic syndrome (CMS), as a bunch of metabolic disorders mainly characterized by type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, central adiposity, and abdominal obesity triggering androgen deficiency, is one of the most critical threats to men. Although many significant preclinical and clinical findings explain CMS, new approaches toward common pathophysiological mechanisms and reasonable therapeutic targets are lacking. To gain a further understanding of the role of androgen levels in various facets of CMS such as the constellation of cardiometabolic risk factors including central adiposity, dyslipidemia, insulin resistance, diabetes, and arterial hypertension and to define future directions for development of effective therapeutic modalities. Clinical and experimental data were searched through scientific literature databases (PubMed) from 2009 to October 2019. Evidence from basic and clinical research was gathered with regard to the causal impact and therapeutic roles of androgens on CMS. There are important mechanisms implicated in androgen levels and the risk of CMS. Low testosterone levels have many signs and symptoms on cardiometabolic and glycometabolic risks as well as abdominal obesity in men. The implications of the findings can shed light on future improvements in androgen levels and add potentially predictive risk for CMS, as well as T2DM, abdominal obesity to guide clinical management in the early stage. This comprehensive review refers to the association between androgens and cardiovascular health. A limitation of this study is the lack of large, prospective population-based studies that analyze the effects of testosterone treatment on CMS or mortality. Low testosterone levels have several common features with metabolic syndrome. Thus, testosterone may have preventive role in the progress of metabolic syndrome and subsequent T2DM, abdominal obesity, and cardiovascular disease and likely affect aging men's health mainly through endocrine and vascular mechanisms. Further studies are necessary to evaluate the therapeutic interventions directed at preventing CMS in men. Kirlangic OF, Yilmaz-Oral D, Kaya-Sezginer E, et al. The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts. Sex Med 2020;XX:XXX–XXX.